Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For example, when the Company discusses the anticipated use of proceeds from the proposed offering, it is using forward-looking statements. Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.Ĭertain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. 333-253808) filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, on March 2, 2021, which registration statement became automatically effective upon filing. 333-235887) previously filed with the Securities and Exchange Commission (“SEC”) on January 10, 2020, which registration statement was declared effective on Januand an additional registration statement on Form S-3MEF (File No. The securities described above were offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. and Colliers Securities LLC acted as co-managers for the offering. JMP Securities, Craig-Hallum Capital Group, and Lake Street Capital Markets, LLC acted as lead managers for the offering and Laidlaw & Company (UK) Ltd. Guggenheim Securities acted as sole book-running manager for the offering. The Company intends to use the net proceeds of the offering for working capital and general corporate purposes. The Company received total gross proceeds from the offering (before deducting the underwriting discounts and offering expenses) of approximately $25.0 million.
(the “Company”, NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the closing on Maof its previously announced underwritten public offering of 1,393,738 shares of common stock at a public offering price of $18.00 per share, which included the exercise in full by the underwriters of their option to purchase up to an additional 171,516 shares of common stock.
Internal applications, then our B2B based Bizapedia Pro API™ might be the answer for you.NASHUA, N.H., Ma(GLOBE NEWSWIRE) - iCAD, Inc.
If you are looking for something more than a web based search utility and need to automate company and officer searches from within your WHAT'S INCLUDED IN THE ADVANCED SEARCH FORM? Utilize our advanced search form to filter the search results by Company Name, City, State, Postal Code, Filing Jurisdiction, Entity Type, Registered Agent,įile Number, Filing Status, and Business Category. While logged in and authenticated, you will not be asked to solve any complicated Recaptcha V2 challenges.
In addition, all pages on Bizapedia will be served to you completely ad freeĪnd you will be granted access to view every profile in its entirety, even if the company chooses to hide the private information on their profile from the general public. Your entire office will be able to use your search subscription.